Clinical significance of Keap1 in cervical cancer.

Q2 Medicine Journal of Buon Pub Date : 2021-09-01

Jing Wang, Xin Li, Yun Zhou, Li Hong

{"title":"Clinical significance of Keap1 in cervical cancer.","authors":"Jing Wang, Xin Li, Yun Zhou, Li Hong","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: To explore the expression of Kelch-like ECH-associated protein 1 (Keap1) and its clinical significance and function in cervical cancer (CC).Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays were used to detect the expression of Keap1 in tissues from CC patients as well as CC cells and control cells in vitro. The relationship between Keap1 expression and CC clinicopathologic characteristics was statistically analyzed. Further, effects of Keap1 on the cell proliferation and apoptosis were evaluated through MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and flow cytometry assay, respectively.Results: Keap1 expression was downregulated in CC and the expression level of Keap1 was associated with stroma invasion, vascular invasion, parametrial invasion, lymph node metastasis and clinical stage. In in vitro study, upregulation of Keap1 in CC cells by transfection could significantly restrict cell proliferation and promote cell apoptosis.Conclusions: Keap1 was a novel factor involved in CC progression, and constituted a potential biomarker and therapeutic target for the CC patients.","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To explore the expression of Kelch-like ECH-associated protein 1 (Keap1) and its clinical significance and function in cervical cancer (CC).

Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays were used to detect the expression of Keap1 in tissues from CC patients as well as CC cells and control cells in vitro. The relationship between Keap1 expression and CC clinicopathologic characteristics was statistically analyzed. Further, effects of Keap1 on the cell proliferation and apoptosis were evaluated through MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and flow cytometry assay, respectively.

Results: Keap1 expression was downregulated in CC and the expression level of Keap1 was associated with stroma invasion, vascular invasion, parametrial invasion, lymph node metastasis and clinical stage. In in vitro study, upregulation of Keap1 in CC cells by transfection could significantly restrict cell proliferation and promote cell apoptosis.

Conclusions: Keap1 was a novel factor involved in CC progression, and constituted a potential biomarker and therapeutic target for the CC patients.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Keap1在宫颈癌中的临床意义。

目的:探讨kelch样ech相关蛋白1 (Keap1)在宫颈癌(CC)中的表达及其临床意义和功能。方法:采用实时荧光定量聚合酶链反应(Quantitative real-time polymerase chain reaction, qRT-PCR)和Western blot检测Keap1在CC患者组织以及CC细胞和对照细胞中的表达。统计学分析Keap1表达与CC临床病理特征的关系。通过MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑)和流式细胞术分别检测Keap1对细胞增殖和凋亡的影响。结果:Keap1在CC中表达下调，表达水平与间质浸润、血管浸润、参数浸润、淋巴结转移及临床分期有关。在体外研究中，转染后上调CC细胞的Keap1可显著抑制细胞增殖，促进细胞凋亡。结论:Keap1是参与CC进展的新因子，是CC患者潜在的生物标志物和治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Buon 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.